logo

Fulcrum Therapeutics (FULC)



Trade FULC now with
  Date
  Headline
8/11/2020 7:17:39 AM Fulcrum Therapeutics Announces Interim Analysis Data From ReDUX4 Trial In Facioscapulohumeral Muscular Dystrophy
7/21/2020 8:02:13 AM MyoKardia, Fulcrum Therapeutics Enter Strategic Collaboration And License Agreement
4/13/2020 7:11:11 AM Fulcrum Complete IND-enabling Safety Studies For FTX-6058 In Sickle Cell Disease
4/2/2020 7:02:54 AM Fulcrum Therapeutics Provides Business Update In Context Of COVID-19
3/5/2020 7:08:51 AM Fulcrum Therapeutics Q4 Net Loss $16.1 Mln Vs Loss $8.9 Mln Last Year
1/29/2020 8:11:32 AM Fulcrum Therapeutics Says FDA Granted Orphan Drug Designation To Losmapimod
1/6/2020 7:12:50 AM Fulcrum Therapeutics Appoints Katina Dorton To Board And As Chair Of The Audit Committee
12/30/2019 7:32:25 AM Acceleron And Fulcrum Therapeutics Announce Pulmonary Research And Discovery Collaboration Agreement
10/4/2019 4:54:28 AM Fulcrum Therapeutics Announced Results Of Phase 1 Clinical Trial Of Losmapimod In FSHD
8/19/2019 7:09:31 AM Fulcrum Therapeutics Initiates ReDUX4, A Phase 2b Clinical Trial Of Losmapimod
7/17/2019 8:55:59 PM Fulcrum Therapeutics Prices IPO Of 4.50 Mln Shares At $16.00/shr
7/13/2019 1:10:19 PM Biotech IPOs For The Week Ahead